Literature DB >> 34713421

Future Offspring Costs in Economic Evaluation.

Evelyn Verbeke1, Jeroen Luyten2.   

Abstract

Economic evaluation guidelines increasingly prescribe inclusion of all future costs. We point at an important dimension of future costs that is systematically neglected. Healthcare can affect future offspring, either through affecting the patient's fertility or through determining future offspring's health. As we show, the future costs associated with these changes can be substantial and will vary across interventions and demographic groups. However, systematic inclusion of these future offspring costs would raise many problems on its own. Based on the population ethics concept of necessitarianism, we suggest that only those future costs that spring from 'necessary' future lives should be included in future cost calculations, while all costs associated with 'potential' future lives can be ignored. This approach allows excluding most future offspring costs and avoids skewed cost-effectiveness outcomes of interventions with fertility effects, while taking into account the economic implications of preventing disease in future generations that will exist by necessity. Overall, future generations expose a substantial gap in today's Health Technology Assessment (HTA) methodology and further discussion of the issues they raise is needed.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Year:  2021        PMID: 34713421     DOI: 10.1007/s40273-021-01102-w

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  26 in total

1.  Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease.

Authors:  Cynthia A Yock; Derek B Boothroyd; Douglas K Owens; Alan M Garber; Mark A Hlatky
Journal:  Am J Med       Date:  2003-10-01       Impact factor: 4.965

2.  Economic foundations of cost-effectiveness analysis.

Authors:  A M Garber; C E Phelps
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

3.  Standardizing the inclusion of indirect medical costs in economic evaluations.

Authors:  Pieter H M van Baal; Albert Wong; Laurentius C J Slobbe; Johan J Polder; Werner B F Brouwer; G Ardine de Wit
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

4.  Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution.

Authors:  Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2019-04       Impact factor: 4.981

5.  Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.

Authors:  Alec Morton; Amanda I Adler; David Bell; Andrew Briggs; Werner Brouwer; Karl Claxton; Neil Craig; Alastair Fischer; Peter McGregor; Pieter van Baal
Journal:  Health Econ       Date:  2016-08       Impact factor: 3.046

6.  Should cost effectiveness analyses for NICE always consider future unrelated medical costs?

Authors:  Pieter van Baal; Alec Morton; Werner Brouwer; David Meltzer; Sarah Davis
Journal:  BMJ       Date:  2017-11-10

7.  Future unrelated medical costs need to be considered in cost effectiveness analysis.

Authors:  Pieter van Baal; Alec Morton; David Meltzer; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2019-02

8.  Estimating comparable English healthcare costs for multiple diseases and unrelated future costs for use in health and public health economic modelling.

Authors:  Adam D M Briggs; Peter Scarborough; Jane Wolstenholme
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

9.  Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

Authors:  Linda M de Vries; Pieter H M van Baal; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

10.  Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary.

Authors:  Erik Nord; Christoffer Lamøy
Journal:  Pharmacoecon Open       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.